©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Jun 10, 2017; 8(3): 230-240
Published online Jun 10, 2017. doi: 10.5306/wjco.v8.i3.230
Published online Jun 10, 2017. doi: 10.5306/wjco.v8.i3.230
Immunotherapy in pancreatic cancer: Unleash its potential through novel combinations
Songchuan Guo, Merly Contratto, George Miller, Lawrence Leichman, Jennifer Wu, Division of Hematology and Oncology, Perlmutter Cancer Center, New York University School of Medicine, New York, NY 10016, United States
Author contributions: Wu J provided the concept, the outline, the structure, and the major references for this manuscript, provided critical revisions for this manuscript; Guo S drafted the majority of the manuscript, incorporated several revisions based on feedback from Wu J, Leichman L and Miller G; Contratto M incorporated essential components into the manuscript and performed critical revisions of this manuscript; Miller G and Lawrence L provided critical feedback and offered major ideas to optimize the manuscript; all authors approved the final manuscript.
Conflict-of-interest statement: There is no conflict of interest associated with any of the senior author or other coauthors contributed their efforts in this manuscript.
Correspondence to: Jennifer Wu, MD, Associate Professor, Division of Hematology and Oncology, Perlmutter Cancer Center, New York University School of Medicine, 462 First Ave, BCD556, New York, NY 10016, United States. jennifer.wu@nyumc.org
Telephone: +1-212-2636530 Fax: +1-212-2638210
Received: January 31, 2017
Peer-review started: February 14, 2017
First decision: March 7, 2017
Revised: March 18, 2017
Accepted: April 18, 2017
Article in press: April 20, 2017
Published online: June 10, 2017
Processing time: 122 Days and 5.1 Hours
Peer-review started: February 14, 2017
First decision: March 7, 2017
Revised: March 18, 2017
Accepted: April 18, 2017
Article in press: April 20, 2017
Published online: June 10, 2017
Processing time: 122 Days and 5.1 Hours
Core Tip
Core tip: Pancreatic cancer is the third leading cause of cancer mortality in both men and women in the United States. Pancreatic cancer is one of nonimmunogenic cancers that lacks of optimal treatments especially from immunotherapy prospective. Therefore, combining immune checkpoint therapies with other treatment modalities in pancreatic cancer will be the best strategy to achieve better and more durable clinical responses by enhancing cytotoxic T-cell responses.